Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year Low – Here’s Why

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) reached a new 52-week low during trading on Tuesday . The company traded as low as $7.93 and last traded at $7.95, with a volume of 50747 shares trading hands. The stock had previously closed at $8.07.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on DAWN shares. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Bank of America lowered their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Wedbush reissued an “outperform” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, HC Wainwright lowered their price target on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $34.57.

Day One Biopharmaceuticals Trading Up 1.5 %

The firm has a fifty day moving average of $11.52 and a two-hundred day moving average of $13.09. The company has a market cap of $890.91 million, a PE ratio of -8.53 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. Sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at $1,531,059.40. This trade represents a 8.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. This represents a 1.70 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,064 shares of company stock valued at $251,925. 8.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DAWN. GF Fund Management CO. LTD. bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $27,000. R Squared Ltd bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $31,000. Quest Partners LLC boosted its position in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after acquiring an additional 7,668 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after acquiring an additional 9,603 shares during the last quarter. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $143,000. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.